首页> 外文期刊>Experimental and clinical endocrinology and diabetes: Official journal, German Society of Endocrinology [and] German Diabetes Association >Hypercortisolism caused by ritonavir associated inhibition of CYP 3A4 under inhalative glucocorticoid therapy2 case reports and a review of the literature
【24h】

Hypercortisolism caused by ritonavir associated inhibition of CYP 3A4 under inhalative glucocorticoid therapy2 case reports and a review of the literature

机译:吸入糖皮质激素治疗下利托那韦相关联的CYP 3A4抑制作用引起的皮质醇过多2例病例报道及文献复习

获取原文
获取原文并翻译 | 示例
           

摘要

Recent in vitro and in vivo studies have shown a potent inhibition of cytochrome P450 CYP3A4 through human immune deficiency virus (HIV) protease inhibitors (PIs). The PI ritonavir is described as the most potent compound within these CYP3A4 inhibitors. We present 2 cases who developed the sequelae of glucocorticoid excess following ritonavir therapy and inhalative glucocorticoid treatment: A 60-year-old HIV positive man developed the typical symptoms of Cushing's syndrome and a 52-year-old HIV positive man developed severe osteoporosis.
机译:最近的体外和体内研究表明,通过人免疫缺陷病毒(HIV)蛋白酶抑制剂(PIs)可以有效抑制细胞色素P450 CYP3A4。 PI ritonavir被描述为这些CYP3A4抑制剂中最有效的化合物。我们目前有2例在利托那韦治疗和吸入性糖皮质激素治疗后出现糖皮质激素过量后遗症的病例:一名60岁的HIV阳性男子出现了库欣综合症的典型症状,一名52岁的HIV阳性男子出现了严重的骨质疏松症。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号